Currently, hormonal therapy [e.g., selective estrogen receptor modulators (SERMs) and aromatase inhibitors] is the mainstay of adjuvant treatment for patients with estrogen receptor–positive (ER+) breast cancer (Chen and Cheung, 2018). The gene discussed is ESR1; the disease is breast cancer.